St. Catherine of Sienna Church - Franklin Square, NY - 5163520146 ...
www.stcatherineofsienna.org/
Sienna Center: St. Catherine's Chapel. A VERY BLESSED CHRISTMAS 2013. MASS SCHEDULE. NEW YEAR'S DAY. Solemnity of Mary, Mother of God.1. Buy the Franklin Square Branch of Nassau OTB to protect the jobs of Franklin Square and nearby locals who work. The business is viable. NY Politicians are not.
2. Improve the healthcare provided to Italians in Italy and residents of Franklin Square and vicinity by combining the work of Dr. Denise L Faustman (see faustmanlab.org and pubmed.org faustman dl) with that
being done in Italy. As you know BCG is safe and effective and may be used to treat and/or prevent a wide variety of autoimmune diseases and allergies. Italy may send BCG to the US while it improves healthcare in both Italy and the US by seeing that BCG is made available to those who need same.
Who needs a bailout when such simple money producing ideas are so easy to find.
Some bet before church. Some don't bet at all. Some shoot BCG and others in NY want to pay a fortune for useless and/or dangerous and/or ineffective healthcare.
Neurology. 2013 Dec 4. [Epub ahead of print]
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS.
Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M, Buttinelli C, Gasperini C, Frontoni M, Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti M.
Abstract
OBJECTIVE:
To evaluate Bacille Calmette-Guérin (BCG) effects after clinically isolated syndromes (CIS).METHODS:
In a double-blind, placebo-controlled trial, participants were randomly assigned to receive BCG or placebo and monitored monthly with brain MRI (6 scans). Both groups then entered a preplanned phase with IM interferon-β-1a for 12 months. From month 18 onward, the patients took the disease-modifying therapies (DMTs) that their neurologist considered indicated in an open-label extension phase lasting up to 60 months.RESULTS:
Of 82 randomized subjects, 73 completed the study (33 vaccinated and 40 placebo). During the initial 6 months, the number of cumulative lesions was significantly lower in vaccinated people. The relative risks were 0.541 (95% confidence interval [CI] 0.308-0.956; p = 0.03) for gadolinium-enhancing lesions (the primary endpoint), 0.364 (95% CI 0.207-0.639; p = 0.001) for new and enlarging T2-hyperintense lesions, and 0.149 (95% CI 0.046-0.416; p = 0.001) for new T1-hypointense lesions. The number of total T1-hypointense lesions was lower in the BCG group at months 6, 12, and 18: mean changes from baseline were -0.09 ± 0.72 vs 0.75 ± 1.81 (p = 0.01), 0.0 ± 0.83 vs 0.88 ± 2.21 (p = 0.08), and -0.21 ± 1.03 vs 1.00 ± 2.49 (p = 0.02). After 60 months, the cumulative probability of clinically definite multiple sclerosis was lower in the BCG + DMT arm (hazard ratio = 0.52, 95% CI 0.27-0.99; p < 0.05), and more vaccinated people remained DMT-free (odds ratio = 0.20, 95% CI 0.04-0.93; p = 0.04).CONCLUSIONS:
Early BCG may benefit CIS and affect its long-term course.CLASSIFICATION OF EVIDENCE:
BCG, as compared to placebo, was associated with significantly reduced development of gadolinium-enhancing lesions in people with CIS for a 6-month period before starting immunomodulating therapy (Class I evidence).- PMID:
- 24306002
- [PubMed - as supplied by publisher]
Neurology. 1999 Oct 22;53(7):1588-9.
Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.
Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese C, Pozzilli C, Salvetti M.
Abstract
We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
Comment in
- Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. [Neurology. 2000]
- PMID:
- 10534275
- [PubMed - indexed for MEDLINE]
Delayed Plans at Italian Bank Muddy Its Fate
By GAIA PIANIGIANI and JACK EWING
Published: December 30, 2013
ROME — The Italian government signaled on Monday that it had no interest
in nationalizing Monte dei Paschi di Siena, the country’s oldest bank,
after shareholders over the weekend overruled bank management and
delayed plans to raise urgently needed cash.
A spokesman for the Italian treasury confirmed on Monday reports that
the government was not eager to take responsibility for the troubled
bank. The government is already dealing with a severe recession and
internal political turmoil.
The Bank of Italy and Consob, which oversees the Italian stock market,
are monitoring events closely, according to an official with knowledge
of the situation. Monte dei Paschi shares closed higher on Monday, but
problems at the bank have the potential to provoke market turmoil in a
country already suffering from a broader banking crisis and a severe
shortage of credit.
The decision by Monte dei Paschi shareholders on Saturday to postpone
the share sale of 3 billion euros (about $4.1 billion) left turnaround
plans for the bank in limbo and raised the possibility that it would not
be able to repay government bailout funds starting in mid-2014.
Debt to the government would then convert to Monte dei Paschi shares, in
effect nationalizing the bank, which has survived numerous wars and
crises since its founding in 1472 but whose future is now in doubt.
On Saturday, shareholders gathered in Siena voted to delay the share
sale at least until May, in accordance with the wishes of the charitable
organization that is Monte dei Paschi’s largest shareholder.
Alessandro Profumo, the chairman of Monte dei Paschi, had argued that
the share sale must be held in January. Investment banks that were set
to underwrite the transaction would not wait any longer than that, he
said.
But the Monte dei Paschi Foundation, which once distributed bank profits
to local charities and other organizations in and around the historic
city of Siena, asked for more time to sell its 33.5 percent stake.
Antonella Mansi, president of the Monte dei Paschi Foundation, said she
thought that a consortium of banks underwriting the share sale would be
willing to wait.
A spokesman for the Swiss bank UBS, the lead bank in the consortium,
said on Monday that it was too early to comment on what the effects of
the delay might be.
Italy’s treasury is trying to facilitate talks between the foundation
and the bank aimed at raising the capital as soon as possible, said a
person with knowledge of the matter.
According to the bank’s plan approved by the treasury and the European
Commission, Monte dei Paschi has to repay €3 billion of the state aid by
the end of 2014.
Luigi Tramontana, an analyst at Banca Akros in Milan, said it could be
more difficult for Monte dei Paschi to issue new shares later in the
year because many other banks would also be trying to raise cash. Banks
in the euro zone are trying to bolster their reserves under pressure
from the European Central Bank, which is undertaking a thorough review
of bank books to uncover hidden problems.
“The rights issue’s postponement increases the uncertainty over the
bank’s ability to avoid full-blown nationalization within a year or so,”
Mr. Tramontana said in a note to clients Monday.
No comments:
Post a Comment